Apimeds Pharmaceuticals US (APUS) Equity Ratio (2023 - 2025)

Apimeds Pharmaceuticals US has reported Equity Ratio for 3 years, with the latest figure at 0.93 in Q4 2025.

• For the quarter ending Q4 2025, Equity Ratio rose 100.9% year-over-year to 0.93; the trailing twelve-month figure through Dec 2025 stood at 0.93 (up 100.9% YoY), and the FY2025 full-year result was 0.93, up 100.9% from the prior year.
• Equity Ratio for Q4 2025 stood at 0.93, up from 0.88 in the prior quarter.
• The five-year high for Equity Ratio was 0.93 in Q4 2025, with the low at 104.01 in Q4 2024.
• Historically, Equity Ratio has averaged 18.0 across 3 years, with a median of 0.48 in 2025.
• Annual changes were most pronounced in 2024 — Equity Ratio tumbled 137858.14% — and 2025, when it surged 100.9%.
• Apimeds Pharmaceuticals US's Equity Ratio stood at 0.08 in 2023, then plunged by 137858.14% to 104.01 in 2024, then jumped by 100.9% to 0.93 in 2025.
• The last three Equity Ratio figures came in at 0.93 (Q4 2025), 0.88 (Q3 2025), and 0.92 (Q2 2025), per Business Quant data.